REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS)

13/08/2025 14:18:02

| LBCTR2019030206 CICL670F2429 MOH registration number 32772/2018 Study registered at the country of origin 32772/2018 Study registered at the country of origin Yes Study registered at the country of origin: Specify Yes Type of registration New of registration in national regulatory agency O1/08/2018 Type of registration: Justify LCTR was recently initiated, original file was previously submit by Paper Date of registration in national regulatory agency O1/08/2018 Primary sponsor: Country of origin Novartis Pharma Services Inc. Date of registration in primary registry 17/12/2019 Date of registration in national regulatory agency 01/08/2018 Date of registration in primary registry 17/12/2019 Date of registration in national regulatory agency 01/08/2018 Public title Selentific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Selentific title Acronym A Single-arm Interventional, prospective, single arm, open label, global, multicenter, non-randomized trial design to monitor and assess the safety origin of the cushed deferasions CT in pediatric patients between age 22 to <6 with transfusional hemosiderosis wor 24 weeks. This study will and to enrol at lasted do patients. Brief summary of the study: Arabic rogical, multicenter, non-randomized trial design to monitor and assess the safety oring withe study agency if with design to monitor and ass | Primary registry identifying number | Protocol number |
|--|--|---|
| عدین العالي Study registered at the country of origin Specify Yes Type of registration Type of registration:: Justify Retrospective LCTR was recently initiated, original file was previously submited by Paper Date of registration in national regulatory agency Specify Station:: Justify Date of registration in national regulatory agency Novartis Pharma Services Inc. Primary sponsor Primary sponsor: Country of origin Novartis Pharma Services Inc. Date of registration in national regulatory agency Date of registration in primary registry Date of registration in national regulatory agency Date of registration in primary registry Date of registration in national regulatory agency Date of registration in primary registry Oate of registration in national regulatory agency Date of registration in primary registry Oate of registration in national regulatory agency Date of registration in primary registry Caronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Acronym Scient Cittle Acronym Scient Study registration and material design to monitor and assess the safety profile of the crushed deferasirox FCI in pediatric Patients With registration and regulatory indit design to monitor and | LBCTR2019030206 | CICL670F2429 |
| Study registered at the country of origin Study registered at the country of origin: Specify Yes Type of registration: Justify Retrospective LCTR was recently initiated, original file was previously submitiby Paper Date of registration in national regulatory agency Date of registration in national regulatory agency 01/08/2018 Primary sponsor: Country of origin Novartis Pharma Services Inc. Novartis Pharmaceuticals Date of registration in primary registry Date of registration in national regulatory agency 11/12/2019 01/08/2018 Public title Acronym Safety Study of Crushed Deferasincs Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Socientific title Acronym A Single-am Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Traeted With Deferasinox Crushed Film Coated Tablets in Pediatics Traeted With Deferasinox Crushed Film Coated Tablets in Paeidatic Patients With Transfusional Hemosiderosis Subject Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis reated With Deferasinox Crushed Film Coated Tablets in Paeidatic Patients With Transfusional Hemosiderosis Ver A weeks, This study will am to enrol at least 40 patients. <td>MOH registration number</td> <td></td> | MOH registration number | |
| Yes Type of registration Type of registration Type of registration:: Justify Retrospective LCTR was recently initiated, original file was previously submi by Paper Date of registration in national regulatory agency 2010/8/2018 Primary sponsor: Country of origin Novartis Pharma Services Inc. Novartis Pharmaceuticals Date of registration in primary registry Date of registration in national regulatory agency 2010/8/2018 Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Acronym Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Praeted With Deferasirox Crushed Film Coated Tablets Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in prediatric patients between age 22 to <6 with transfusional hemosiderosis Sover 24 weeks. This study will arm to enrol at leas 40 patients. Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirs FCT in prediatric patients between age 22 to <6 with transfusional hemosiderosis Sover 24 weeks. This study will arm to enrol at leas t40 patients. Brief summary of the study. Langua, Langua | 32772/2018 | |
| Type of registration Type of registration: Justify Retrospective LCTR was recently initiated, original file was previously submit by Paper Date of registration in national regulatory agoncy of the study is pharma Services Inc. Primary sponsor: Country of origin Novartis Pharma Services Inc. Novartis Pharmaceuticals Date of registration in primary registry Date of registration in national regulatory agency 17/12/2019 Otto 8 Public title Acronym Sefert Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Scientific title Selentific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study assess the safety of Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Selentific title Acronym Selef study of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety of Pediatric Patients With Transfusional Hemosiderosis sover 24 weeks. This study will alm to errol at least 40 patients Brief summary of the study: Arabic Capacity and the crushed deferasions ACT in pediatric patients acrospective, single arm open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasions ACT in pediatric patients acroby acrospectiv | Study registered at the country of origin | Study registered at the country of origin: Specify |
| Retrospective LCTR was recently initiated, original file was previously submitive paper Date of registration in national regulatory agency 01/08/2018 Primary sponsor Primary sponsor Primary sponsor: Country of origin Novartis Pharma Services Inc. Novartis Pharmaceuticals Date of registration in primary registry Date of registration in national regulatory agency 01/08/2018 Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Acronym Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Brief summary of the study: English Acronym The study employs an interventional, prospective, single arm, open tablets for prove and weeks. This study will aim to errol at least 40 patients. Brief summary of the study: English The study employs an interventional, prospective, single arm, open tablet, global, multicenter, non-randomized trial design to monitor and assess the safety of the crushed deferasions CTCT in pediatric patients. Brief summary of the study: Arabic Hemosiderosis Brief summary of the study: Markin Transfusional Hemosiderosis Hender Study endities between age 22 to <6 with transfusional hemosiderosis | Yes | |
| by Paper Date of registration in national regulatory agency 01/08/2018 Primary sponsor Primary sponsor: Country of origin Novartis Pharma Services Inc. Novartis Pharmaceuticals Date of registration in primary registry Date of registration in national regulatory agency 11/12/2019 Date of registration in national regulatory agency 11/12/2019 Oti/08/2018 Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Brief summary of the study: English The study employs an interventional, prospective, single arm, open label, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age 22 to <6 with transfusional hemosiderosis bore 24 weeks. This study will aim to enroli at least 40 patients. Brief summary of the study: Arabic Brief summary of the study: Specify Brief summary of the study: Specif | Type of registration | Type of registration: Justify |
| age of 2010/08/2018 Primary sponsor Primary sponsor: Country of origin Novartis Pharma Services Inc. Novartis Pharmaceuticals Date of registration in primary registry Date of registration in national regulatory agency 17/12/2019 01/08/2018 Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Acronym Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Acronym Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age 22 to 46 with transfusional Hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic asters breaked ty acting ional fueronitio and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age 22 to 46 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic asters before analytic and acting in a fueronitio and assess the safety profile of the crushed deferasirox FCT in pediatric patients betweene age 22 to 46 with transfusional hemosiderosis </td <td>Retrospective</td> <td>LCTR was recently initiated, original file was previously submitted by Paper</td> | Retrospective | LCTR was recently initiated, original file was previously submitted by Paper |
| Novartis Pharma Services Inc. Novartis Pharmaceuticals Date of registration in primary registry Date of registration in national regulatory agency 17/12/2019 01/08/2018 Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Acronym Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Acronym Brief summary of the study: English The study employs an interventional, prospective, single arm, open Iabled, global, multicenter,non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: ArabiC apatients between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: ArabiC apatients between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: ArabiC apatients between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: ArabiC apatient between age (20000000000000000 | agency | |
| Date of registration in primary registry Date of registration in national regulatory agency 17/12/2019 01/08/2018 Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Acronym Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Acronym Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and abasess the safety profile of the crushed deferasirox FCT in pediatric patients between age 22 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic Brief summary of the study: Arabic patients between age 22 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic Patients materia (study in the on the at lates to patients) Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age 22 to <6 with transfusional Hemosiderosis over 24 weeks. This study will aim to enrol at least 40 patients. Brief summary | Primary sponsor | Primary sponsor: Country of origin |
| 17/1/12/2019 01/08/2018 Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Acronym Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Acronym Puemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Brief summary of the study: English The study employs an interventional, prospective, single arm, open Iabel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age 2: 0 to <% with transfusional Hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. | Novartis Pharma Services Inc. | Novartis Pharmaceuticals |
| Public title Acronym Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Acronym Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age ≥ 10 < 60 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic Industry in the study enploys an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic sover 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic industry in the of Intervent Industry in the | Date of registration in primary registry | Date of registration in national regulatory agency |
| Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric battents between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic Industry of the study: Arabic Brief summary of the study: Arabic Brief summary of the study: Arabic Brief summary of the study: Arabic Industry interventional, Incomparing and the one of the operation of the ope | 17/12/2019 | 01/08/2018 |
| Pediatric Patients With Transfusional Hemosiderosis (MIMAS) Scientific title Acronym A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter,non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric batients between age ≥2 to <6 with transfusional hemosiderosis sover 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic Brief summary of the study: Arabic Health conditions/problem studied: Specify Transfusional Hemosiderosis | Public title | Acronym |
| A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric batients between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic steff summary of the study: Arabic exclusive functional f | | |
| Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Brief summary of the study: English The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic steff summary of the study: Arabic number of the study: Arabic Immune Tit, and the quadent in a company of the study. The quadent is a set of the study is a set of the study. The set of the study is a set of the study is a set of the study is a set of the study. The set of the study is a set of the study is a set of the study. The set of the study is a set of the study is a set of the study is a set of the set of | Scientific title | Acronym |
| The study employs an interventional, prospective, single arm, open abel, global, multicenter, non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric batients between age ≥2 to <6 with transfusional hemosiderosis over 24 weeks. This study will aim to enroll at least 40 patients. Brief summary of the study: Arabic scene the study: Arabic curve the study of the study: Arabic multicenter intervention of the curve of the defension of the study of the study of the study of the study intervention of the study of the st | Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated | |
| المعلوم المعالجين بالحد الدموي (الهيموسيدروسز) المعنوبي الم | Brief summary of the study: English | |
| دراسة تدخلية وحيدة المجموعة في المرحلة الرابعة بعد الترخيص لتقييم سلامة المرضى الاطفال المصابين بالحدد الدموي (الهيموسيدروسز) ذي الصلة بنقل الدم والمعالجين بأقر اص ديفيرازيروكس المسحوقة المعلقة بطبقة رقيقة Health conditions/problem studied: Specify Transfusional Hemosiderosis | label, global, multicenter,non-randomized trial design to monitor and assess the safety profile of the crushed deferasirox FCT in pediatric patients between age ≥2 to <6 with transfusional hemosiderosis | |
| الصلة بنقل الدم والمعالجين بأقراص ديفيرازيروكس المسحّوقة المغلفة بطبقة رقيقة Health conditions/problem studied: Specify Transfusional Hemosiderosis | Brief summary of the study: Arabic | |
| Transfusional Hemosiderosis | | در اسة تدخلية وحيدة المجموعة في المرحل |
| | Health conditions/problem studied: Specify | |
| Interventions: Specify | Transfusional Hemosiderosis | |
| | Interventions: Specify | |
| Drug: Deferasirox Deferosirox is provided in tablet forms of 90, 180 and 360mg. Tablets must be crushed. | 0 | ust be crushed. |
| | Other Name: ICL670 | |

1.Patients ≥2 to <6 years old diagnosed with transfusional hemosiderosis

 \sim

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

2.Documented history of red blood cell transfusions

3.Written informed consent/assent before any study-specific procedures. The consent will be obtained from caregiver(s) or patient's legal representative. Investigators will also obtain assent of patients according to local, regional, or national regulations. 4.For patients on prior DFX: Serum ferritin (SF) >500 ng/mL, measured at screening visit 1 and requiring a DFX daily dose equivalent to FCT ≥ 7mg/kg/day.

5.For patients on a prior chelator other than DFX (e.g. deferiprone or deferoxamine) or chelation naive: Serum ferritin (SF) >1000 ng/mL measured at screening visits 1 and 2.

| Key inclusion and exclusion criteria: Gender | Key inclusion and exclusion criteria: Specify gender |
|---|--|
| Both | |
| Key inclusion and exclusion criteria: Age minimum | Key inclusion and exclusion criteria: Age maximum |
| 2 | 6 |

Key inclusion and exclusion criteria: Exclusion criteria

1.Patients that receive more than one iron chelator at the same time as current iron chelation treatment. (Patients who have received combination therapy in their medical history but are currently being treated with a single ICT agent are eligible.)

2.Patients continuing on deferoxamine or deferiprone in addition to study treatment.

(Patients switching to or continuing on deferasirox are eligible).

3. Unresolved adverse events if the patient was previously treated with deferiprone or deferoxamine or deferasirox.

4. Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a non-first void sample urine measured at screening visit 1.

5.Serum creatinine > age adjusted ULN measured at any screening visit

6.Creatinine clearance below 90 mL/minute measured at any screening visit. Creatinine clearance using the Schwartz formula will be estimated from serum creatinine measured at each respective visit.

7.ALT and/or AST > 2.5 x ULN measured at screening visit 1.

8.Total bilirubin (TBIL) >1.5 x ULN measured at screening visit 1.

9.Patients with significant impaired GI function or GI disease that may significantly alter the absorption of oral deferasirox FCT (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).

10. History of and/or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positive with HCV RNA positive.

11.Liver disease with severity of Child-Pugh Class B or C.

12. History of hypersensitivity to any of the study drug or excipients.

13.Patients participating in another clinical trial or receiving an investigational drug.

14.Patients with a known history of HIV seropositivity.

15.Patients unwilling or unable to comply with the protocol.

16. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.

17. Significant medical condition interfering with the ability to partake in this study (e.g.

uncontrolled hypertension, unstable cardiac disease not controlled by standard medical therapy, systemic disease: cardiovascular, renal, hepatic, etc.).

18.Female patients who reach menarche and they or their caregivers refuse pregnancy testing and/or if there is a positive pregnancy test result.

Type of study

Interventional

| Type of intervention | Type of intervention: Specify type |
|--------------------------|------------------------------------|
| Pharmaceutical | N/A |
| Trial scope | Trial scope: Specify scope |
| Therapy | N/A |
| Study design: Allocation | Study design: Masking |
| N/A: Single arm study | Open (masking not used) |
| Study design: Control | Study phase |
| N/A | 4 |
| Study design: Purpose | Study design: Specify purpose |

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

| Treatment | N/A | |
|--|--|------------------------|
| Study design: Assignment Single | Study design: Specify assignment N/A | |
| IMP has market authorization | IMP has market authorization: | Specify |
| Yes, Lebanon and Worldwide | USA, UK, France, Germany, Net Italy | |
| Name of IMP | Year of authorization | Month of authorization |
| Deferasirox Film Coated Tablets "Jadenu" | 2017 | 10 |
| Type of IMP Others | | |
| Pharmaceutical class Non-chiral, Tridentate ligand iron chelator | | |
| Therapeutic indication Iron Over Load | | |
| Therapeutic benefit Treatment of Iron Overload symptoms | | |
| Study model N/A | Study model: Explain model N/A | |
| Study model: Specify model N/A | | |
| Time perspective N/A | Time perspective: Explain time | e perspective |
| Time perspective: Specify perspective N/A | | |
| Target follow-up duration | Target follow-up duration: Unit | t |
| Number of groups/cohorts | | |
| Bissessimon retention | Biognosimon des suisties | |
| Biospecimen retention None retained | Biospecimen description Local Lab tests at site | |
| | | |
| | | |
| Target sample size 3 | Actual enrollment target size | |
| Date of first enrollment: Type | Date of first enrollment: Date | |

| panon Clinical Trials Registry |
|--------------------------------|
| |

| Actual | 10/10/2018 |
|---|--|
| Date of study closure: Type Actual | Date of study closure: Date 11/03/2020 |
| Recruitment status Complete | Recruitment status: Specify |
| Date of completion 17/05/2019 | |
| IPD sharing statement plan No | IPD sharing statement description undecided |
| Additional data URL https://clinicaltrials.gov/ct2/show/record/NCT03372083?id=CICL670F2429&i Admin comments | rank=1&view=record |
| Trial status | |

Approved

| Secondary Identifying Numbers | | | |
|--------------------------------|------------------------------|--|--|
| Full name of issuing authority | Secondary identifying number | | |
| Clinical Trials. gov | NCT03372083 | | |

| Sources of Monetary or Material Support |
|---|
| Name |
| Novartis Pharma Services Inc. |
| |

| Secondary Sponsors | |
|--------------------|--|
| Name | |
| NA | |



| Contac | Contact for Public/Scientific Queries | | | | | | |
|-----------------|---------------------------------------|------------|---------|------------------------------|-----------------------------------|------------------------------------|--|
| Contact type | Contact full name | Address | Country | Telephone | Email | Affiliation | |
| Public | Ali Taher | Beirut | Lebanon | 009613755 669 | ataher@aub.edu. lb | Chronic Care Center | |
| Scientific | Hind Khairallah | Sin El Fil | Lebanon | +961 1 512002 Ext. 271 | Hind.Khairallah@ fattal.com.lb | Khalil Fattal et Fils s.a.l. | |

| Centers/Hospitals Involved in the Study | | | | |
|--|--------------|------------------------------------|------------------|--|
| Center/Hospital name Name of principles investigator | | Principles investigator speciality | Ethical approval | |
| Chronic Care Center | Dr Ali Taher | Hematology | Approved | |

| Ethics Review | | | | | |
|---|------------|------------------|---------------------------|--------------------------------|--|
| Ethics approval obtained Approval date | | Contact name | Contact email | Contact phone | |
| Chronic Care Center | 26/07/2018 | Michele Abi saad | cccmas@chroniccare.org.lb | +961 3 664 310 | |
| American University of Beirut Medical Center | 05/07/2018 | Fuad Ziyadeh | fz05@aub.edu.lb | +961 (0) 1 350 000 ext:5445 | |

| Countries of Recruitment |
|--------------------------|
| Name |
| Egypt |
| Lebanon |
| Italy |
| Oman |
| Russian Federation |
| Saudi Arabia |
| Thailand |
| United Arab Emirates |



| Health Conditions or Problems Studied | | | | |
|---------------------------------------|-----------------------------------|-----------------------------|--|--|
| Condition | Code | Keyword | | |
| Transfusional Hemosiderosis | Thalassaemia, unspecified (D56.9) | Transfusional Hemosiderosis | | |

| Interventions | | | | |
|--|--|--|--|--|
| Intervention | Description | Keyword | | |
| Physical examination, Vitals, Height, Weight, Hematology, Chemistry, urinalisis, ECG, Ocular assessment, Auditory assessment | Physical examination, Vitals, Height, Weight, Hematology, Chemistry, urinalisis, ECG, Ocular assessment, Auditory assessment | ICF, IMP, Lab tests , diary completion | | |

| Primary Outcomes | | | | |
|--|-----------------------|-----------------------|--|--|
| Name | Time Points | Measure | | |
| Percentage of patients with selected gastrointestinal disorders | 24 weeks | 24 wks | | |
| To assess the safety of crushed deferasirox FCT with respect to selected gastrointestinal (GI) disorders | through out the study | through out the study | | |

| Key Secondary Outcomes | | | |
|--|-------------|----------|--|
| Name | Time Points | Measure | |
| Percentage of patients who experienced AEs suspected to be related to study drug | 24 weeks | 24 wks | |
| •Change from baseline ECGs up | 24 weeks | 24 weeks | |
| •Change from baseline serum ferritin (SF) | 24 weeks | 24 weeks | |
| •Absolute change for serum creatinine | 24 weeks | 24 weeks | |
| •Absolute change for creatinine clearance UPCR | 24 weeks | 24 weeks | |
| Palatability Questionnaire Score | 24 weeks | 24 weeks | |



Trial Results Summary results Study results globally Date of posting of results summaries Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files